about
Radioisotopes in management of metastatic prostate cancerHeptamethine carbocyanine dye-mediated near-infrared imaging of canine and human cancers through the HIF-1α/OATPs signaling axisComparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternativesEGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides.Prognostic Utility of PET in Prostate Cancer.A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomyMeasuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancerTranslational Molecular Imaging of Prostate Cancer.Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer.The fat side of prostate cancer.Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer.Synergistic action of image-guided radiotherapy and androgen deprivation therapy.Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer.New prospects for PET in prostate cancer imaging: a physicist's viewpoint.NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics.PET imaging of recurrent and metastatic prostate cancer with novel tracers.Imaging features of Paget's disease on 11C choline PET/CT.Quantitative graphical analysis of simultaneous dynamic PET/MRI for assessment of prostate cancer.Tumor necrosis factor-α-induced a disintegrin and metalloprotease 10 increases apoptosis resistance in prostate cancer cells.Writing PET into existence.
P2860
Q28068134-39F4FEA5-F8C7-4CE4-BC58-A8A4B5301659Q30303040-0FF3CDF6-98EE-40CD-BD8E-9AEB6302EEF0Q34228828-10EF866D-7C0D-4F7A-8921-B4935C433D9CQ34473460-676981D6-6F60-4EC6-BAB3-5B69ED0F4D38Q35184816-26CDB445-C1EF-428C-B0A0-4EC6A01A7099Q35244433-46AA75D8-7752-490E-92A9-99AA8138309AQ35544056-0507F918-B37C-4FBF-8722-9999D9B4A57CQ36429530-DFFA1665-783C-4EBC-A488-F1D1AE3DD6ECQ36738856-A8769A8F-F32B-427A-B130-ED802EB96173Q37244969-60461DC2-FD2B-4436-A7CA-27081936A1C1Q37617965-FF3EBAEE-CC63-43EC-9721-0753C7D74C56Q38096735-CCC3C420-A415-4852-9375-C43522F01264Q38256977-D55D329E-969D-4D3D-98A1-1C883B513D96Q38387844-87107994-3318-4B8A-8FDA-92E52B622FFCQ38547110-72687BE2-428E-40F5-A374-97EA7B23A0F2Q38616392-F608474E-8C47-4D9A-BF86-76E751398C5EQ38767020-5BAEE9D9-DFE2-421A-9D3F-5976F706A6B9Q38831029-B932A498-E378-4A99-B665-6005D07A4A78Q41019269-7C63632E-BB0A-43EC-911E-EF564B4DE2D7Q41548893-0CF3082D-8AD3-40CB-BD6A-52FDAC0BE983Q41890825-99A01628-3CBF-4E17-A8F2-B016043BB06EQ53094162-25390BE4-9F5A-42B4-947A-96E694284F44
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Molecular imaging of prostate cancer.
@en
type
label
Molecular imaging of prostate cancer.
@en
prefLabel
Molecular imaging of prostate cancer.
@en
P2093
P2860
P1476
Molecular imaging of prostate cancer.
@en
P2093
Heiko Schöder
Josef J Fox
Steven M Larson
P2860
P304
P356
10.1097/MOU.0B013E32835483D5
P577
2012-07-01T00:00:00Z